Blog

Learn 10 essential steps you can take to protect your brand in today’s business world.

A company’s brand is one of its most valuable strategic assets and one of its most visible ones. Learn the importance of the scope and power of your brand and how to move toward success.

Learn how to assess your firm’s readiness to identify and exploit its IP capabilities using a set of questions related to Intellectual Property.

Dear Clients and Colleagues, During this time of uncertainty and anxiety, we just wanted to let you know that your friends at Dilworth IP are available to assist you in whatever way we can. We wanted to share this quick bulleted list of updates for you. As of last Tuesday, […]

Dr. Anthony Sabatelli & David Puleo will be presenting a free webinar on Thursday, April 19th at 1:00 PM (ET) for Dilworth IP, entitled, “Just What is the Federal Circuit Thinking? A Path Forward Amid Subject Matter Eligibility Variability.” Tens of millions spent on product development – how do you protect your company’s technology in an environment where the Federal Circuit redefines patent eligible subject matter on nearly a weekly basis, and where the USPTO’s application of these judgments is just as inconsistent? Is subject matter eligibility no longer a question of law and is it now morphing into a question of fact?

On Wednesday, President Obama signed the Defend Trade Secrets Act. His action follows the bill’s passage in Congress, which we previously reported here: /trade-secrets-bill-passes-house-goes-white-house/

In a signing ceremony in the Oval Office, President Obama recognized the legislation’s historic importance, commenting that the law “for the first time will provide civil actions for companies or individuals that are stealing trade secrets from our American innovators[1].”

On Wednesday, April 27, the House of Representatives voted 410-2 to approve the Defend Trade Secret Act (S. 1890). The bipartisan measure, which is supported by the White House, is expected to be signed into law in the coming days.

On May 5th, the US Patent and Trademark Office published an update to the Interim Guidance titled “May 2016 Subject Matter Eligibility Update” to provide its examining corps with additional guidelines for determining subject matter eligibility under 35 USC §101.

The publication includes a memorandum, “Formulating a Subject Matter Eligibility Rejection and Evaluating the Applicant’s Response to a Subject Matter Eligibility Rejection,” which “seeks to improve examiner correspondence with regard to subject matter eligibility rejections.” It was issued in response to public comments.

The story continues to unfold regarding the patent eligibility of diagnostics, a story that first made headlines in the fall of 2013. Back then, the District Court for the Northern District of California issued an Order holding that medical diagnostic method claims are not eligible for patent protection (“The Sequenom Decision”).1 The decision was noteworthy, because it had been made upon remand and direction from the Federal Circuit to examine the patent eligibility of diagnostics in light of the Supreme Court’s now infamous Myriad and Mayo decisions.

In an interesting case decided last week, the Federal Circuit ruled that it cannot address whether the US Patent and Trademark Office’s 2014 Interim Guidance on Patent Subject Matter Eligibility exceeds the scope of the Supreme Court’s decisions in this area.